Pildralazine_product_DataBase

Bioactivity	Pildralazine (Propyldazine) is a hydralazinelike antihypertensive vasodilator containing a free hydrazine group. Pildralazine is orally active, has no significant carcinogenicity in mice model[1][2].
In Vivo	Pildralazine (6-43 mg/kg; p.o.; once daily) shows no significant carcinogenicity in B6C3F1 and BALB/c mice under a long-term bioassay and a transplacental-infantile bioassay[1].Pildralazine and Hydralazine (HY-B0464A) act on a common receptor,sensitive to endogenous ATP and adenosine in the isolated tail artery from normotensive Wistar (NW) rats[2].Pildralazine (1 mg/kg; p.o.; ) significantly inhibits the onset of severe hypertension in spontaneously hypertensive rats (SHR) model[3]. Animal Model:
Name	Pildralazine
CAS	64000-73-3
Formula	C8H15N5O
Molar Mass	197.24
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Della Porta G, Dragani TA. Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound. J Cancer Res Clin Oncol. 1983;106(2):97-101. [2]. Chevillard C, et al. Interactions between hydralazine, propildazine and purines on arterial smooth muscle. Br J Pharmacol. 1981 Aug;73(4):811-7. [3]. Dorigotti L, et al. Effects of pildralazine alone and in combination on severe hypertension and cerebrovascular lesions in saline-drinking spontaneously hypertensive rats. Arzneimittelforschung. 1984;34(8):876-9.

PeptideDB